The Biospecimen and Pathology Core provides part of the infrastructure support for the major projects comprising the Pacific Northwest Prostate Cancer SPORE as well as for research conducted through the developmental research and career enhancement programs. It has been designed to meet the needs of these projects and serve as a resource for collaborative efforts with other SPOREs. This Core will provide a systematic and standardized system of specimen collection, storage, distribution and related clinical/research information dissemination that is based on over two decades of experience. There will be consistency and quality assurance in the pathological analysis of tissue specimens. This Core has 5 components: 1. Clinical specimen acquisition (i.e. tissues, including those from surgery and the rapid autopsy program, serum, plasma and urine), processing, quality control, storage, distribution and database entry; 2. A program to continually improve the quality and efficiency of biospecimen acquisition, processing and storage to increase the fidelity of specimens provided to the SPORE investigators; 3. Maintain prostate cancer xenograft lines established by the Core and make specimens available for biological study and/or perform pre-clinical studies for SPORE investigators and collaborators; 4. Laboratory services, including production of tissue microarrays, interpretation of immunohistology by urologic pathologists, production of specimen derivatives and perform PSA immunoassays for research; 5. An administrative program to obtain samples from minorities, prioritize the distribution of specimens, ensure patient confidentiality and compliance with IRB requirements, maintain and improve quality control measures and interact with other SPOREs. Specimens from our repository, especially those from our rapid autopsy program (e.g. PC bone metastases) and our LuCaP series of prostate cancer xenografts have been, and will continue to be distributed to other PC investigators on an international basis.

Public Health Relevance

The performance of translational research mandates that investigators have ready access to well documented clinical specimens and relevant biological models. The Biospecimen Core directors have decades of experience in recognizing these needs and providing such services not only to local investigators but to those who request specimens on a world-wide basis these interactions will continue. This will truly enhance the translational aspects of our NW Prostate Cancer SPORE.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA097186-18
Application #
10016181
Study Section
Special Emphasis Panel (ZCA1)
Project Start
2002-09-19
Project End
2023-08-31
Budget Start
2020-09-01
Budget End
2021-08-31
Support Year
18
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Barnard, Monique; Quanson, Jonathan L; Mostaghel, Elahe et al. (2018) 11-Oxygenated androgen precursors are the preferred substrates for aldo-keto reductase 1C3 (AKR1C3): Implications for castration resistant prostate cancer. J Steroid Biochem Mol Biol 183:192-201
Ganaie, Arsheed A; Beigh, Firdous H; Astone, Matteo et al. (2018) BMI1 Drives Metastasis of Prostate Cancer in Caucasian and African-American Men and Is A Potential Therapeutic Target: Hypothesis Tested in Race-specific Models. Clin Cancer Res 24:6421-6432
Schweizer, Michael T; Haugk, Kathleen; McKiernan, Jožefa S et al. (2018) A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer. PLoS One 13:e0198389
Peacock, James W; Takeuchi, Ario; Hayashi, Norihiro et al. (2018) SEMA3C drives cancer growth by transactivating multiple receptor tyrosine kinases via Plexin B1. EMBO Mol Med 10:219-238
Pollan, Sara G; Huang, Fangjin; Sperger, Jamie M et al. (2018) Regulation of inside-out ?1-integrin activation by CDCP1. Oncogene 37:2817-2836
Wu, Yi-Mi; Cie?lik, Marcin; Lonigro, Robert J et al. (2018) Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer. Cell 173:1770-1782.e14
Schweizer, Michael T; Hancock, Michael L; Getzenberg, Robert H et al. (2018) Hormone levels following surgical and medical castration: defining optimal androgen suppression. Asian J Androl 20:405-406
Yan, Qingxiang; Bantis, Leonidas E; Stanford, Janet L et al. (2018) Combining multiple biomarkers linearly to maximize the partial area under the ROC curve. Stat Med 37:627-642
Lam, Hung-Ming; Nguyen, Holly M; Corey, Eva (2018) Generation of Prostate Cancer Patient-Derived Xenografts to Investigate Mechanisms of Novel Treatments and Treatment Resistance. Methods Mol Biol 1786:1-27
Lam, Hung-Ming; Corey, Eva (2018) Supraphysiological Testosterone Therapy as Treatment for Castration-Resistant Prostate Cancer. Front Oncol 8:167

Showing the most recent 10 out of 400 publications